RxDoctor Payments Data

Amber Soto

Medical · Amarillo, TXNPI 1578634424

Payments from drug & device makers

$1,193in general payments, 2019–2025

Across 20 payments — averaging $59.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$257
  • Novartis$249
  • Biotronik Inc.$197
  • Boehringer Ingelheim$195
  • Abiomed$97
  • Genentech USA, Inc.$75
  • plus $124 from 4 others

What the payments were for

  • Food & beverage$1,06689%
  • Education$12711%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,193 in reported general payments places this provider in the 60th percentile of 1,490 medical providers in Texas.

See all medical providers in Texas

Medicare billing

Part B allowed, 2024
$171,702
Medicare patients
876
Services billed
1,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan271$231,280
EliquisApixaban183$157,866
JardianceEmpagliflozin54$62,583
XareltoRivaroxaban14$17,715
BrilintaTicagrelor14$17,113
Carvedilol362$2,322
Atorvastatin Calcium168$1,704
Metoprolol Succinate88$1,509
ClopidogrelClopidogrel Bisulfate140$1,505
Potassium Chloride100$1,300
Isosorbide Mononitrate ErIsosorbide Mononitrate89$1,255
Spironolactone178$1,169
Rosuvastatin Calcium178$1,155
Prasugrel Hcl11$902
Hydralazine Hcl43$857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$249$231,280271 claims
Boehringer IngelheimJardiance$195$62,58354 claims
AstraZenecaBrilinta$14$17,11314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,490 medical providers in Texas.

Other medical in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →